Search Within

Genitourinary Oncology Service

  1. "Han Xiao"
Formats
  1. Meeting Abstract (33)
  2. Journal Article (28)
  3. Book Section (1)
Groups
  1. Department of Medicine (62)
  2. Solid Tumor Oncology Division (62)
  3. Epidemiology and Biostatistics (22)
  4. Survivorship Research (21)
  5. Biostatistics Service (17)
  6. Radiology, Department of (17)

More Groups

People
  1. Han Xiao (62)
  2. Eric Sherman (13)
  3. David Pfister (12)
  4. Matthew Fury (11)
  5. Dean Bajorin (10)
  6. Sofia Haque (10)

More People

Years
  1. 2025 (4)
  2. 2024 (6)
  3. 2023 (6)
  4. 2022 (5)
  5. 2021 (4)
  6. 2020 (5)

More Years

Publications
  1. Journal of Clinical Oncology (29)
  2. Annals of Oncology (5)
  3. Cancer (3)
  4. Head & Neck (2)
  5. Investigational New Drugs (2)
  6. Proceedings of the American Association for Cancer Research Annual Meeting (2)

More Publications

Publishers
  1. American Society of Clinical Oncology (31)
  2. Oxford University Press (6)
  3. Wiley Blackwell (3)
  4. American Association for Cancer Research (2)
  5. Elsevier Inc. (2)
  6. John Wiley & Sons, Inc. (2)

More Publishers

Results (62)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A phase 1b/2 study of intermittent talazoparib plus temozolomide in patients with metastatic castration-resistant prostate cancer and no mutations in DNA damage response genes
    Journal Article

    Autio, K. A.; Kyriakopoulos, C. E.; Palyca, P.; Xiao, H.; Emamekhoo, H.; Danila, D.; Jan, M.; Catharine, V.; Riedel, E.; Devitt, M.; more...
    Investigational New Drugs (2025)

    Fulltext@MSK | Save
  • The role of healthcare system distrust in shaping patients' attitudes and beliefs of artificial intelligence (AI) use in oncology
    Meeting Abstract

    Santos Teles, M.; Bryl, K. L.; Chimonas, S.; Khan, A. J.; Epstein, A. S.; Daly, R. M.; Xiao, H.; Mao, J. J.
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Real-world clinical outcomes of sacituzumab govitecan after prior exposure to enfortumab vedotin in patients with metastatic urothelial carcinoma
    Journal Article

    Sternschuss, M.; Toumbacaris, N.; Das, J. P.; Powles, T.; Kotecha, R. R.; Laccetti, A. L.; Xiao, H.; Feld, E.; McHugh, D. J.; Keegan, N. M.; more...
    ESMO Open (2025)

    Fulltext@MSK | Save
  • Olaparib and durvalumab in patients with DNA damage repair alterations and biochemically recurrent prostate cancer
    Journal Article

    Autio, K. A.; McHugh, D. J.; Rathkopf, D. E.; Xiao, H.; Merugu, S.; Wong, P.; Jan, M.; Dorff, T. B.; Heath, E. I.; Scher, H. I.
    Journal of Immunotherapy and Precision Oncology (2025)

    Fulltext@MSK | Save
  • Clinical outcomes of patients with metastatic urothelial carcinoma (mUC) discontinuing enfortumab vedotin (EV) monotherapy (mono) without disease progression
    Meeting Abstract

    Sternschuss, M.; Whiting, K.; Teo, M. Y.; Bajorin, D.; Kotecha, R.; Laccetti, A. L.; Xiao, H.; Feld, E.; McHugh, D. J.; Keegan, N.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Final clinical and liquid biopsy (LBx) results of phase II trial of sacituzumab govitecan (SG) in patients (Pts) with metastatic castration resistant prostate cancer (mCRPC) progressing on androgen receptor signaling inhibitors (ARSI)
    Meeting Abstract

    Lang, J. M.; Tagawa, S. T.; Slovin, S.; Sperger, J. M.; Schehr, J. L.; Stahlfeld, C.; Hintz, A. M.; Emamekhoo, H.; Rathkopf, D.; Abida, W.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Health-related quality of life (HRQOL) results from PRESTO (AFT-19), a phase 3 randomized trial of intensification of androgen blockade in patients with high-risk biochemically relapsed castration sensitive prostate cancer
    Meeting Abstract

    Chen, R. C.; Mazza, G. L.; Fruth, B.; Xiao, H.; Picus, J.; Taplin, M. E.; Dorff, T. B.; Appleman, L. J.; Weckstein, D. J.; Patnaik, A.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Clinical outcomes of sacituzumab govitecan (SG) after prior exposure to enfortumab vedotin (EV) in patients with metastatic urothelial carcinoma (mUC)
    Meeting Abstract

    Sternschuss, M.; Toumbacaris, N.; Das, J. P.; Powles, T.; Bajorin, D. F.; Kotecha, R. R.; Laccetti, A. L.; Xiao, H.; Feld, E.; McHugh, D. J.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • A phase 2 trial of talazoparib and avelumab in genomically defined metastatic kidney cancer
    Journal Article

    Kotecha, R. R.; Doshi, S. D.; Knezevic, A.; Chaim, J.; Chen, Y.; Jacobi, R.; Zucker, M.; Reznik, E.; McHugh, D.; Shah, N. J.; more...
    European Urology Oncology (2024)

    Fulltext@MSK | Save
  • PRESTO: A phase III, open-label study of intensification of androgen blockade in patients with high-risk biochemically relapsed castration-sensitive prostate cancer (AFT-19)
    Journal Article

    Aggarwal, R.; Heller, G.; Hillman, D. W.; Xiao, H.; Picus, J.; Taplin, M. E.; Dorff, T.; Appleman, L.; Weckstein, D.; Patnaik, A.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save